BRIEF—Rare Pediatric Priority Review Voucher (PPRV) advances

While marking up 23 bills yesterday, the House Energy & Commerce Committee’s (E&C) Health Subcommittee approved  H.R. 7384 to extend the  PPRV program, which incentivizes R&D by giving vouchers to expedite review of pediatric rare disease drugs.

Trade group the Biotechnology Innovation Organization (BIO) said it was pleased to see legislation to reauthorize the PPRV for six years pass with a bipartisan vote. As Members of Congress on both sides of the aisle shared, the PPRV is a critical tool in incentivizing the development of treatments for rare pediatric diseases.

The BIO urges Congress to pass the legislation before it expires on September 30, the end of the fiscal year.